Ind-Swift Laboratories Limited — Others, 11-11-2024: Statement of deviation(s) or variation(s) under Reg. 32

Ind-Swift Laboratories Ltd has confirmed that there was no deviation in the utilization of funds raised through a preferential issue of convertible warrants amounting to ₹78.73 crore during the quarter ended September 30, 2024. The funds were deployed according to the objectives outlined without any discrepancies. This positive update reflects effective financial management and compliance, potentially enhancing investor confidence as it demonstrates accountability and alignment with stated financial goals. The continuation of planned expenditures suggests a stable outlook for the company's operational strategy.